Anavex Life Sciences (NASDAQ:AVXL) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15), Yahoo Finance reports. During the same quarter in the previous year, the company posted ($0.10) earnings per share.
AVXL stock traded up $1.02 during midday trading on Thursday, reaching $18.99. 1,391,200 shares of the company were exchanged, compared to its average volume of 2,249,869. Anavex Life Sciences has a 1-year low of $4.51 and a 1-year high of $31.50. The stock’s 50-day simple moving average is $19.02 and its 200 day simple moving average is $18.77. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -39.56 and a beta of 0.68.
AVXL has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Anavex Life Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, October 13th. HC Wainwright reiterated a “buy” rating and issued a $39.00 price target on shares of Anavex Life Sciences in a research note on Thursday, October 14th. Finally, BTIG Research reiterated a “buy” rating and issued a $34.00 price target on shares of Anavex Life Sciences in a research note on Thursday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $29.89.
About Anavex Life Sciences
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.